| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
GlycoNex Incorporation (TWO: 4168)
4168 Technical Analysis
2
| As on 15th Dec 2025 4168 STOCK Price closed @ 23.65 and we RECOMMEND Buy for LONG-TERM with Stoploss of 23.42 & Strong Sell for SHORT-TERM with Stoploss of 24.61 we also expect STOCK to react on Following IMPORTANT LEVELS. |
4168STOCK Price
| Open | 21.50 | Change | Price | % |
| High | 23.65 | 1 Day | 2.15 | 10.00 |
| Low | 21.50 | 1 Week | 1.80 | 8.24 |
| Close | 23.65 | 1 Month | 1.10 | 4.88 |
| Volume | 859175 | 1 Year | -0.60 | -2.47 |
| 52 Week High 30.45 | 52 Week Low 15.75 | ||||
TWO Taiwan Most Active Stocks
| 5498 | 32.30 | 9.86% |
| 1815 | 83.50 | -1.07% |
| 8358 | 274.00 | 2.05% |
| 3105 | 183.00 | 0.55% |
| 3163 | 388.00 | -2.76% |
| 5309 | 69.60 | -2.93% |
| 6244 | 20.40 | 9.97% |
| 8043 | 83.30 | 0.85% |
| 3260 | 186.00 | 0.27% |
| 4979 | 255.00 | -2.11% |
TWO Taiwan Top Gainers Stocks
TWO Taiwan Top Losers Stocks
| 4168 Daily Charts |
4168 Intraday Charts |
Whats New @ Bazaartrend |
4168 Free Analysis |
|
|
4168 Important Levels Intraday
| RESISTANCE | 27.79 |
| RESISTANCE | 26.46 |
| RESISTANCE | 25.64 |
| RESISTANCE | 24.82 |
| SUPPORT | 22.48 |
| SUPPORT | 21.66 |
| SUPPORT | 20.84 |
| SUPPORT | 19.51 |
4168 Forecast December 2025
| 4th UP Forecast | 29.14 |
| 3rd UP Forecast | 27.38 |
| 2nd UP Forecast | 26.29 |
| 1st UP Forecast | 25.2 |
| 1st DOWN Forecast | 22.1 |
| 2nd DOWN Forecast | 21.01 |
| 3rd DOWN Forecast | 19.92 |
| 4th DOWN Forecast | 18.16 |
4168 Weekly Forecast
| 4th UP Forecast | 25.29 |
| 3rd UP Forecast | 24.76 |
| 2nd UP Forecast | 24.44 |
| 1st UP Forecast | 24.11 |
| 1st DOWN Forecast | 23.19 |
| 2nd DOWN Forecast | 22.86 |
| 3rd DOWN Forecast | 22.54 |
| 4th DOWN Forecast | 22.01 |
4168 Forecast2025
| 4th UP Forecast | 53.23 |
| 3rd UP Forecast | 43.74 |
| 2nd UP Forecast | 37.88 |
| 1st UP Forecast | 32.02 |
| 1st DOWN Forecast | 15.28 |
| 2nd DOWN Forecast | 9.42 |
| 3rd DOWN Forecast | 3.56 |
| 4th DOWN Forecast | -5.93 |
GlycoNex Incorporation ( TWO Taiwan Symbol : 4168 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
4168 Business Profile
GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycosphingolipid antigen production and identification; monoclonal antibody production; cancer drug screening; stable cell line production for monoclonal antibody; and pharmacology/pharmacokinetics assessment. The company offers GNX102, a humanized antibody for cancer-specific glycan prevalent on several types of cancer cells, such as gastric, colon, and pancreatic cancer, as well as develops bi-specific antibody generate armed T-cells targeting glycan antigens on cancer cells. GlycoNex Incorporation was founded in 2001 and is based in New Taipei City, Taiwan. Address: No. 97, Xintai 5th Road, New Taipei City, Taiwan, 221
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service